Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Ertapenem in an Elastomeric Infusion Device

Author(s):  Phipps Stephen D, Peacock Gina F, Smith Douglas L

Issue:  May/Jun 2011 - Volume 15, Number 3
View All Articles in Issue

Page(s):  252-254

Stability of Ertapenem in an Elastomeric Infusion Device Page 1
Stability of Ertapenem in an Elastomeric Infusion Device Page 2
Stability of Ertapenem in an Elastomeric Infusion Device Page 3

Download in electronic PDF format for $75

Abstract:  Ertapenem is an intravenous antibiotic that is dosed once daily and is utilized in the home infusion setting for parenteral antibiotic therapy. Thepurpose of this study was to evaluate the stability of ertapenem in an elastomeric infusion device over a one-week period. A stability-indicating high-performance liquid chromatographic method for ertapenem was identified from the literature and evaluated in our laboratory. Under our experimental conditions, the method demonstrated acceptable precision (1.8% relative standard deviation) and linearity (r2 = 0.998). Five 1-g vials of commercial grade ertapenem were reconstituted with 10 mL of sterile water for injection according to the manufacturer’s directions and then transferred into an elastomeric infusion device along with 90 mL of 0.9% sodium chloride solution (concentration of 10 mg/mL). After preparation of the ertapenem solutions, the five elastomeric infusion devices were stored under refrigerated conditions (5oC). Ertapenem concentrations were assayed in duplicate at the time of initial preparation and at subsequent 24-hour intervals throughout the study. Ertapenem concentrations were quantified by interpolation from a standard curve; ertapenem standard curves were generated each day of the study from solutions of known ertapenem concentration that were prepared from ertapenem analytical standard. At the 72-hour time point, ertapenem concentrations from each of the five elastomeric infusion pumps remained greater than 90% of initial concentration. At the 120-hour time point, the overall average ertapenem concentration was 90.4% of initial concentration, but two out of the five concentrations were below 90% of initial concentration. At the end of the 7-day study, the overall average ertapenem concentration was 88.9% of initial concentration and only one concentration was greater than 90% of initial concentration. Based on the results from this study, a beyond-use date of 3 days (72 hours) is conservatively recommended for ertapenem solutions prepared in Homepump ECLIPSE elastomeric infusion devices that are stored under refrigerated conditions.

Related Keywords: Stephen D. Phipps, PharmD, PhD, Gina F. Peacock, PhD, Douglas L. Smith, PharmD, BCNSP, BCOP, ertapenem, antibiotic, stability, intravenous administration, home infusion, elastomeric infusion device, storage conditions


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Stability of Ertapenem in an Elastomeric Infusion Device
Phipps Stephen D
, Peacock Gina F, Smith Douglas L
May/Jun 2011
Pg. 252-254

In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers
Bhattacharya Sisir
, Parekh Satish, Dedhiya Mahendra
Sep/Oct 2015
Pg. 432-436

Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device
Tsiouris Maria
, Ulmer Marisa, Yurcho James F, Hooper Kevin L, Gui Min
Sep/Oct 2010
Pg. 436-439

Disposable Ambulatory Infusion Devices: A Review - Part 3
Ashworth Lisa D
Nov/Dec 2000
Pg. 442-443

Home Infusion Basics for the Non-Infusion Pharmacist
Miron Karen E
Mar/Apr 2011
Pg. 94-100

Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump
Tomasello Cristina
, Leggieri Anna, Rabbia Franco, Veglio Franco, Baietto Lorena, Fulcheri Chiara, De Nicolò Amedeo, De Perri Giovanni, D'Avolio Antonio
Jul/Aug 2016
Pg. 343-346

Home Infusion: Available Vascular Access Devices and Common Therapies
Kennedy Steve
, Williams LaVonn A
May/Jun 2011
Pg. 183-188

Ambulatory Pumps: Part I of a Three-Part Series - Peristaltic Infusion Devices Review
Ashworth Lisa D
Jul/Aug 2000
Pg. 281-285

Ambulatory Syringe Infusion Devices: A Review - Part 2
Ashworth Lisa D
Sep/Oct 2000
Pg. 364

Stability of Ampicillin Sodium, Nafcillin Sodium, and Oxacillin Sodium in AutoDose Infusion System Bags
Zhang Yanping
, Trissel Lawrence A
May/Jun 2002
Pg. 226-229

Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags
Kaiser Jeanette
, Kramer Irene
Nov/Dec 2011
Pg. 515-520

Home Infusion 101
Williams LaVonn A
Jan/Feb 2011
Pg. 6-10

Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags
Marquis Kathleen
, Hohlfelder Benjamin, Szumita Paul M
Sep/Oct 2017
Pg. 436-439

Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags
Breukels Oscar
, van der Gronde Toon, Simons-Sanders Kathleen, Crul Mirjam
Jul/Aug 2018
Pg. 345-349

Stability of Gentamicin Sulfate and Tobramycin Sulfate in AutoDose Infusion System Bags
Xu Quanyun A
, Trissel Lawrence A, Saenz Christopher A, Ingram Delshalonda S
Mar/Apr 2002
Pg. 152-154

Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal)
Garrigue Philippe
, Montana Marc, Ventre Christophe, Savry Amadine, Gauthier-Villano Laurence, Pisano Pascale, Pourroy Bertrand
Mar/Apr 2016
Pg. 148-154

Home Infusion: Overview of the Infusion Patient-Care Process
Kennedy Steve
Jul/Aug 2011
Pg. 270-276

Comparison of Three Reconstitution Devices: A Simulated Time and Use Study
Penoyer Daleen
, Giuliano Karen, Middleton Aurea
Mar/Apr 2023
Pg. 169-174

Home Infusion: Overcoming the Barriers to Entry
Franklin David M
Nov/Dec 2010
Pg. 450-455

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Return to Top